April 5, 2023 07:05 AM EDTUpdated 08:42 AM
People

Fol­low­ing clin­i­cal set­backs, NGM Bio lays off 33% of staffers as founder de­parts

Amber Tong

NGM Bio hint­ed at fi­nan­cial strain at the end of Feb­ru­ary when it an­nounced 2022 fi­nan­cial re­sults, not­ing a nar­rowed fo­cus on on­col­o­gy and an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times